Introduction: Financing through understanding
IP's intangible nature does little to bolster investor confidence in biotechnology. Roya Ghafele, who works as an economist at WIPO, says that biotechnology is insufficiently funded due to a lack of awareness of the value of patents among both borrowers and investors
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: